RareStone Medicine

RareStone Medicine is a China-based biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare diseases. Founded in 2018 through a strategic partnership involving Viela Bio and a consortium of investors, the company focuses on addressing significant unmet medical needs within the Chinese market. Its lead product, Uplizna (inebilizumab), is approved in China for the treatment of neuromyelitis optica spectrum disorder (NMOSD). RareStone leverages a combination of in-licensing and internal development to build a robust pipeline targeting autoimmune, inflammatory, and neuromuscular rare conditions. The company aims to become a leading platform for rare disease solutions in Greater China by bridging the gap between global innovation and local patient access.